|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Head and Neck Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Head and Neck Neoplasms | |||||
| Nasopharyngeal Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Nasopharyngeal Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Otorhinolaryngologic Diseases | |||||
| Otorhinolaryngologic Neoplasms | |||||
| Pharyngeal Diseases | |||||
| Pharyngeal Neoplasms | |||||
| Stomatognathic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| pazopanib hydrochloride | |||||
| computed tomography | |||||
| pharmacological study | |||||
| 5 | Sponsors listed in this trial | ||||
| Cancer Therapeutics Research Group | |||||
| National Cancer Institute (NCI) | |||||